金沙检测线路js95(中国)股份有限公司-Official website

You are about to leave Peijia Medical's official Chinese website.
You have just clicked on a link to another website. After clicking Continue, you may be taken to a website run by a third party. We are not responsible for the review and control of content outside Peijia Medical's official Chinese website, nor do we assume any responsibility for business transactions or matters conducted outside Peijia Medical's official Chinese website. The use of other websites is subject to the terms of use and privacy policies of those websites. Certain products or information found on other websites may not be approved for your region or country.
Cancel
Continue
Brief News on Innovation
Company News Brief News on Innovation
NTCVR Multicenter Study Confirmed Safety and Efficacy of Taurus NCPI Technology in Pure Regurgitation Intervention
2025-10-28 09:18:54

At TCT 2025, Professor Zhang Xiaochun from Zhongshan Hospital, representing the teams of Academician Ge Junbo, Professor Zhou Daxin, and Professor Pan Wenzhi, presented groundbreaking research titled "Noncoronary Sinus Pivot Implantation (NCPI) Strategy for TAVR with Self-Expanding Valve in Pure Native Aortic Regurgitation." 

The study demonstrated that using the NCPI strategy with the self-expanding TaurusElite valve system in pure native aortic regurgitation (PNAR) patients significantly improved device success rates and reduced complication risks, offering a new global solution for AR intervention.

The innovative NCPI technique establishes a stable pivot above the noncoronary sinus base, enabling stable valve deployment and anchoring while allowing the lower valve edge to extend into the LVOT and right coronary sinus for improved coaptation and support. Results showed the NCPI group achieved a remarkable 98.8% device success rate, significantly outperforming the non-NCPI group's 81.1% (p<0.001).


Top
XML 地图